Literature DB >> 24330085

Structural findings and molecular modeling approach of a TFPI-like inhibitor.

Kerly Fernanda Mesquita Pasqualoto, Andrea Balan, Sandra Alves Barreto, Simone Michaela Simons, Ana Marisa Chudzinski-Tavassi1.   

Abstract

Specific blood coagulation inhibitors from hematophagous organisms, with different structures and novel mechanism of action, have been described and they represent promising agents for the treatment of a variety of human diseases related to coagulation and cancer. In our lab, the salivary glands transcriptome of the adult Amblyomma cajennense tick was previously characterized by expressed sequence tags (EST). A transcript that codes for a tissue factor pathway inhibitor (TFPI)-like protein with unique structure was found, and the recombinant form of this protein was named Amblyomin-X. This protein was able to inhibit the factor Xa amidolytic activity and the activation of factor X by the extrinsic tenase complex (FVIIa/TF). Herein, it was performed functional and structural evaluation of Amblyomin-X. The CD assay and molecular dynamics simulations revealed that Amblyomin-X is structurally stable and the naturally unfolded regions as well as the presence of three disulfide bridges in its Kunitz-type domain seem to sustain its inhibitory activity. Regarding the electrostatic potential mapping on the Kunitz-type region, the pattern of charged residues was not quite the same in comparison to human TFPI-1 and TFPI-2, pointing out there might be distinct functional and structural features, which are going to be experimentally exploited.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24330085     DOI: 10.2174/0929866520666131210115334

Source DB:  PubMed          Journal:  Protein Pept Lett        ISSN: 0929-8665            Impact factor:   1.890


  3 in total

1.  Quarterly intrinsic disorder digest (April-May-June, 2014).

Authors:  Shelly DeForte; Vladimir N Uversky
Journal:  Intrinsically Disord Proteins       Date:  2017-03-01

2.  S. mansoni SmKI-1 Kunitz-domain: Leucine point mutation at P1 site generates enhanced neutrophil elastase inhibitory activity.

Authors:  Fábio Mambelli; Bruno P O Santos; Suellen B Morais; Enrico G T Gimenez; Duana C Dos S Astoni; Amanda D Braga; Rafaela S Ferreira; Flávio A Amaral; Mariana T Q de Magalhães; Sergio C Oliveira
Journal:  PLoS Negl Trop Dis       Date:  2021-01-19

Review 3.  A Kunitz-type inhibitor from tick salivary glands: A promising novel antitumor drug candidate.

Authors:  Aline R M Lobba; Miryam Paola Alvarez-Flores; Melissa Regina Fessel; Marcus Vinicius Buri; Douglas S Oliveira; Renata N Gomes; Priscila S Cunegundes; Carlos DeOcesano-Pereira; Victor D Cinel; Ana M Chudzinski-Tavassi
Journal:  Front Mol Biosci       Date:  2022-08-16
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.